Pilot Study About Safety and Efficacy of Atomized Intrapleural Lidocaine During Pleuroscopy
A Pilot Study About Safety and Efficacy of Atomized Intrapleural Lidocaine During Pleuroscopy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Burlington, Massachusetts, United States, 01805
- Lahey Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with pleural disease
- Patients undergoing pleuroscopy with talc with or w/o biopsy
- Patients aged 18 - 85
- Patients capable of signing informed consent
Exclusion Criteria:
- Severe congestive heart failure
- Hepatic failure, bilirubin > 2mg/dl, ALT,AST 3XULN
- Prior use Lidocaine in 48 hrs
- Hx SA drug reaction to lidocaine or amide local anesthetics
- Second or third degree heart block (w/o pacemaker)
- Sever sinoatrial block (w/o pacemaker)
- Concurrent treatment with quinidine, flecainide, dsopyramide, procainamide (ClassI antirrhythmic agents)
- Prior use or amiodarone hydrochloride
- systolic BP < 90mmHg
- bradycardia
- accelerated idioventricular rhythm
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Standard anesthesia group
Patients randomized to arm 1 received standard of care anesthesia for pleuroscopy.
Duration of the procedure will be recorded.
Pain management will be monitored prior to, intraoperatively and at the end of the procedure.
|
|
|
Experimental: Lidocaine Group
Patients randomized to arm two will receive a reduced topical dose of lidocaine of 2mg/kg and additional lidocaine 3mg/kg infused into the pleura cavity.
Duration of procedure will be monitored from the time initial dose of intradermal lidocaine until the start of surgical wound closing, pain scale will be administered prior to the procedure and at the end of the procedure.
Lidocaine serum levels will be monitored at 30, 60, and 120 minutes after initial intradermal administration of lidocaine.
|
Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity.
The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg.
Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improve pain management in patients undergoing pleuroscopy
Time Frame: pre-procedure and post procedure
|
pre-procedure and post procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Reduction of procedure time Measurement of lidocaine serum levels at 30, 60, 120
Time Frame: time of procedure will be documented;lidocaine levels monitored throught out
|
time of procedure will be documented;lidocaine levels monitored throught out
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: David R Riker, MD, Lahey Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
Other Study ID Numbers
- LCID 2008-007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.